Business
Eupraxia Pharmaceuticals Inc. Reports Fourth Quarter and Full Year 2021 Financial Results
Eupraxia Pharmaceuticals Inc. Reports Fourth Quarter and Full Year 2021 Financial Results...
About this update from Eupraxia Pharmaceuticals, Inc.
[{"type":"text","content":"\n \n \n \n Eupraxia Pharmaceuticals Inc. Reports Fourth Quarter and Full Year 2021 Financial Results\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n VICTORIA, BC\n \n \n ,\n \n \n March 29, 2022\n \n \n /CNW/ - Eupraxia Pharmaceuticals Inc. (\"Eupraxia\" or the \"Company\") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced its audited financial results (prepared in accordance with International Financial Reporting Standards or \"IFRS\") and operational highlights for the fourth quarter and year ended\n \n December 31, 2021\n \n . All amounts are expressed in Canadian dollars unless otherwise noted.\n \n \n \"In 2021, we significantly strengthened our balance sheet and moved our large Phase 2 study with EP-104IAR into active patient dosing,\" said Dr.\n \n James Helliwell\n \n , CEO of Eupraxia. \"Late in 2021, we proactively decided to expand the number of participating countries and trial sites to strengthen patient accrual to the trial, which is now expected to readout in the first quarter of 2023. In parallel with the trial, we continue to evaluate opportunities to expand our pipeline, leveraging the versatility and capability of our core platform delivery technology.\"\n \n \n \n \n Selected Operational and Financial Highlights for the Fourth Quarter\n \n \n \n \n \n The Company received CTA acceptance to expand its ongoing Phase 2 clinical trial for EP-104IAR into\n \n Poland\n \n and\n \n Czech Republic\n \n and is opening additional sites in\n \n Denmark\n \n to accelerate patient screening. The trial is evaluating EP-104IAR's safety and efficacy for the treatment of pain due to osteoarthritis of the knee.\n \n \n The\n \n National Research Council\n \n of Canada Industrial Research Assistance Program (\"NRC-IRAP\") approved up to\n \n $700,000\n \n in funds and advisory services received to support further research and development of the Company's proprietary polymer-based drug delivery technology.\n \n \n Eupraxia filed and obtain...